These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Secondary C-kit mutation is a cause of acquired resistance to imatinib in gastrointestinal stromal tumor.
    Author: Zheng S, Pan YL, Tao DY, Wang JL, Huang KE.
    Journal: Scand J Gastroenterol; 2009; 44(6):760-3. PubMed ID: 19096980.
    Abstract:
    C-kit gene gain of function mutations are important in the pathogenesis of gastrointestinal stromal tumors (GISTs). Imatinib is a selective tyrosine kinase inhibitor of KIT and achieves a partial response or stable disease in most patients with metastatic GIST, but there is increasing evidence of acquired resistance. We report a case of GIST with acquired resistance to imatinib during therapy and secondary c-kit mutation besides the primary mutation.
    [Abstract] [Full Text] [Related] [New Search]